Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Primary Biliary Cirrhosis Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Primary Biliary Cirrhosis Overview | 8 | 1 |
| Primary Biliary Cirrhosis Therapeutics under Development by Companies | 9 | 1 |
| Primary Biliary Cirrhosis Pipeline Products Glance | 10 | 4 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Unknown Stage Products | 13 | 1 |
| Primary Biliary Cirrhosis Products under Development by Companies | 14 | 1 |
| Primary Biliary Cirrhosis Companies Involved in Therapeutics Development | 15 | 13 |
| AlbireoPharma | 15 | 1 |
| CymaBay Therapeutics, Inc. | 16 | 1 |
| Dr. Falk Pharma GmbH | 17 | 1 |
| Enanta Pharmaceuticals, Inc. | 18 | 1 |
| Genextra S.p.a. | 19 | 1 |
| GenKyoTex S.A. | 20 | 1 |
| GlaxoSmithKline Plc | 21 | 1 |
| MediGene AG | 22 | 1 |
| NGM Biopharmaceuticals, Inc. | 23 | 1 |
| Novartis AG | 24 | 1 |
| Shire Plc | 25 | 1 |
| TGV-Laboratories | 26 | 1 |
| Virobay Inc. | 27 | 1 |
| Primary Biliary Cirrhosis Therapeutics Assessment | 28 | 9 |
| Assessment by Monotherapy Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 33 |
| A-4250 Drug Profile | 37 | 2 |
| budesonide Drug Profile | 39 | 3 |
| EDP-305 Drug Profile | 42 | 1 |
| FFP-104 Drug Profile | 43 | 1 |
| GKT-831 Drug Profile | 44 | 3 |
| GSK-2330672 Drug Profile | 47 | 1 |
| Hep-114 Drug Profile | 48 | 1 |
| LJN-452 Drug Profile | 49 | 1 |
| maralixibat chloride Drug Profile | 50 | 3 |
| MBX-8025 Drug Profile | 53 | 3 |
| NGM-282 Drug Profile | 56 | 2 |
| obeticholic acid Drug Profile | 58 | 9 |
| RhuDex Drug Profile | 67 | 2 |
| VBY-825 Drug Profile | 69 | 1 |
| Primary Biliary Cirrhosis Dormant Projects | 70 | 1 |
| Primary Biliary Cirrhosis Product Development Milestones | 71 | 18 |
| Featured News &Press Releases | 71 | 1 |
| May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC) | 71 | 1 |
| May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC | 72 | 1 |
| May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016 | 73 | 2 |
| Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL | 75 | 1 |
| Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC | 76 | 1 |
| Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016 | 77 | 2 |
| Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn s Disease with anti-CD40 Monoclonal Antibody | 79 | 1 |
| Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC | 80 | 1 |
| Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015 | 80 | 1 |
| Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis | 81 | 1 |
| Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015 | 82 | 1 |
| Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting | 83 | 2 |
| Aug 31, 2015: FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis | 85 | 1 |
| Jun 29, 2015: Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis | 86 | 1 |
| Apr 13, 2015: Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015 | 87 | 2 |
| Appendix | 89 | 2 |
| Methodology | 89 | 1 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 89 | 1 |
| Expert Panel Validation | 89 | 1 |
| Contact Us | 89 | 1 |
| Disclaimer | 90 | 1 |